The Latest Cardiac and Vascular News
Issuance of U.S. Patent 11,247,902 B2 Further Bolsters JanOne Inc.’s Intellectual Patent Portfolio LAS VEGAS, June 7, 2022 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that a patent was […]
JanOne’s management is encouraged regarding Recent Discussions on Potential Phase 2b Trial Endpoints and Possible Regulatory Routes for JAN101 as Treatment for Peripheral Artery Disease (PAD) LAS VEGAS, Sept. 28, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company that focuses on the development […]
Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA LAS VEGAS, June 23, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions […]
Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne’s Phase 2b Trial Preparedness and Execution LAS VEGAS, June 22, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain […]
Update on plans for sale of recycling business. Divesting will allow for focus on core life science assets LAS VEGAS, Sept. 16, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with […]
Bottling and labeling partner Eurofins CDMO (Alphora Research, Inc.) to ensure JanOne clinical research maintains compliance with GMP and FDA regulations LAS VEGAS, Sept. 3, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe […]
Engineering batch for JAN101 complete and expectations are for GMP batch production to begin within 30 days LAS VEGAS, Aug. 26, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with […]
JAN101 formulation ready for Phase 2b peripheral artery disease trials and for potential treatment of COVID-19 vascular inflammation LAS VEGAS, Aug. 11, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and […]
Study to Explore JAN101’s Potential to Treat Ischemia¹ and Endothelial dysfunction² in COVID-19 patients. LAS VEGAS, Aug. 6, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving […]
